As per our report, the global high throughput screening market size is anticipated to grow at 7.8% CAGR from 2020 to 2025. The market was valued at USD 16.21 billion in 2020 and is expected to reach USD 23.6 billion by 2025.
High throughput screening is a drug discovery technique used for evaluation and screening of a large number of biological modulators and effectors against a selected target. Over the last couple of years, high throughput screening has gained extensive usage and has become a standard method of drug discovery in the pharmaceutical industry. The main idea behind this technique is to accelerate the drug discovery process by screening a large number of compound libraries such as combinatorial chemistry, genomics, protein, and peptide libraries at a rate that may exceed a few thousand compounds per day or week. These methods are also used to describe metabolic, pharmacokinetic, and toxicological data for new drugs and thereby eventually to reduce the cost of drug development. High throughput screening comprises of several steps such as target identification, reagent preparation, compound management, assay development, and high-throughput library screening.
MARKET DRIVERS
Growing initiatives by pharmaceutical and biotechnology firms, increased R&D spending, technological improvements, rising government support, and venture capital investments are primarily fuelling the global HTS market growth.
Factors such as technological advancements in the automation of liquid handling, the creation of novel technological platforms, and the development of analytical tools to deal with massive quantities of data have exponentially driven the market for high throughput screening devices market. The growing competition among pharma companies has led to an increased demand for high throughput screening devices. HTS market is expected to witness positive growth due to its inevitable use in the research and production field. Furthermore, the increasing demand in research, substantial capital investments in the HTS technology, the rise in outsourced drug discovery services, and the growing utilization rate of HTS technologies by pharmaceutical companies are key factors aiding the high throughput screening market growth.
In the last few years, open innovation strategies have been implemented by the pharmaceutical and biotechnology industries to collaborate with educational and research institutions on drug discovery methods. Academic institutions carry out target identification and verification work in this open innovation approach, while pharmaceutical companies carry out advanced screening campaigns and production of HTS assays. All pharmaceutical companies and the academy benefit from this strategy. A cooperative approach includes the determination of clinical value targets for basic biology, new target recognition, and stem cell therapy replacement.
Through this strategy, pharmaceutical companies can improve their drug discovery by increasing testing efficiency and performance. At the same time, academic institutes can continue their work with the aid of large data sets present in large pharmaceutical companies' public domain. It is therefore expected that the growing adoption of HTS in pharmaceutical & biotechnology companies and educational & research institutes will drive the growth of the HTS industry.
MARKET RESTRAINTS
Be that as it may, the capital-intensive nature, need for extensive automation techniques, and high regulatory intervention and costs are turning out to be restraints for the high throughput screening market.
RECENT DEVELOPMENTS IN THE INDUSTRY:
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Technology, Application, Product, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This market research report on the global high throughput screening market has been segmented based on the technology, application, product, end-user, and region.
High Throughput Screening Market - By Technology
High Throughput Screening Market - By Application
High Throughput Screening Market - By Product
Based on the product, the Consumables and reagents segment held the largest share of the products and services market. The presence of a wide range of reagents and continual product developments and innovations contributes to their most significant share in the HTS products and services market.
High Throughput Screening Market - By End User
Based on end-users, the pharmaceutical and biotechnology companies segment held the largest share of the market by end-users. The widespread use of HTS technology in pharmaceutical and biotechnology companies for drug discovery applications is the primary factor driving the growth of this market.
High Throughput Screening Market - By Region
Regionally, North America held the largest share of the global high throughput screening market, followed by Europe, and the Asia Pacific. Growth in the developed regions such as North America and Europe is primarily driven by the massive spending on pharmaceutical R&D and high adoption of HTS and availability of government funding, and the presence of major companies in this region.
Asia Pacific is expected to register the highest CAGR during the forecast period. Latin America is projected to witness lucrative growth in the coming years. It can be attributed to the growing R&D spending, the rising trend of outsourcing drug discovery services, growing public-private partnerships, and increasing government funding.
TOP COMPANIES IN THE MARKET
The market is dominated by companies like Agilent Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Tecan Group Ltd., Millipore, Bio-Rad Laboratories, Hamilton Company, Axxam S.p.A., and Aurora Biomed.
Related Reports
